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A variety of disturbances in cell-mediated immunity have been found in Type 1 diabetes, including cellular hypersensitivity to pancreatic extract [1] , cytotoxic effects of diabetic lymphocytes against insulinoma cells [2] and alterations in subsets of peripheral blood lymphocytes [3] [4] [5] [6] [7] . Studies in Type 1 diabetes and other autoimmune diseases have suggested that antibodies directed against lymphocytes may play a part in the pathogenesis of these disorders [8, 9] . Warm and coldreacting autoantibodies against T and B cells have been found in diabetic sera [10] , and an IgG against lymphocytes has been identified in the BB Wistar rat [11] . Similar antibodies have been described in other autoimmune diseases but the pathogenic significance of these antibodies and their relationship to disturbances in peripheral blood lymphocyte subsets has not been defined. The present study was designed to address these questions.
Subjects and methods

Subjects
Peripheral blood lymphocyte subpopulations were measured in three groups of diabetic patients and 14normal control subjects. The patients included: (a) 15 Type1 diabetic patients of recent onset (aged 3-23 years; within 4 months of presentation). The mean C-peptide level was 0.28_+0.01 nmol/l [13] ; HbA1 was 10.0+0.5% [14] ; seven had anti-thyroid antibodies (anti-microsomal haemagglutination and anti-thyroglobulin haemagglutination) [15] . 
Preparation and staining of peripheral blood lymphocytes
Mononuclear cells were isolated from 20 ml of peripheral blood using Ficoll/Paque by standard methods [16] . The cells were stained either phycoerythrin conjugated with anti-Leu 2a or 3 a or fluorescein isothiocyanate (FITC) conjugated with anti-Leu 4, 7 or 11 a (Becton Dickinson, Monoctonal Center, Mountain View, California) according to established procedures [16] . These recently characterized antibodies specify cytotoxic/suppressor T cells, helper/inducer T cells, large granular lymphocytes and natural killer cells (HNK-1 antigen), and neutrophil and natural killer cell FcIgG receptors respectively [12] . Controls included cells incubated with media alone. The cells were analysed on a FACS IV.5 (Becton Dickinson, FACS Division, Mountain View, California, USA). 20,000 cells were analysed in duplicate and the mean data expressed as a percentage are reported.
Staining of anti-lymphoeyte antibodies
Peripheral blood lymphocytes were isolated from three normal donors as described above and pooled. Heat-inactivated ultracentrifuged sera from Type 1 diabetic patients of recent onset or control subjects was incubated with cells for 1 h at 4 ~ After washing, the cells were stained with FITC conjugated goat F(ab) 2 anti-human IgG (Fc fragment specific) which was pre-absorbed with mouse immunoglobulin. The cells 'were washed and then stained with phycoerythrin anti-Leu 2a or 3a. Negative control cells included lymphocytes stained with FITC anti-IgG and phycoerythrin conjugated anti-Leu 2 a or 3 a. As a positive control, rabbit anti-thymocyte globulin in a 1 : 50 dilution was used in the place of sera. 30,000 cells were analysed for two colour immunofluorescence on the instrument noted above with gates set on lymphocyte peaks of forward and wide angle scatter. The number of dual colour fluorescent cells was calculated using a Textronix computer (model 4025, Textronix, Beaverton, Oregon, USA). Each serum sample was assayed on three occasions with the same cell donors and the mean number of dual colour cells is reported.
Statistical analysis
The significance of differences between patient groups and control subjects were evaluated by unpaired t-tests or Wilcoxon scores. All results are expressed as mean + SEM.
Results
Lymphocyte subpopulations
The quantitative analysis of lymphocyte subpopulations is seen in Table 1 . Leu 3a levels were significantly reduced in the Type 1 diabetic patients of recent onset (p< 0.02) compared with the control subjects and diabetic patients of longer duration (p<0.05), and unchanged in Type 2 diabetic patients. Leu 2a levels were not different from control subjects in any of the diabetic groups. Reduced numbers of Leu 4 cells were seen in the diabetic patients of longer duration (p< 0.05). Although, as a group, significant differences in Leu 7 or 1 la cells were not seen in the recent onset Type 1 diabetic patients, there was a clear tendency for strikingly low values in patients with diabetes of short duration. Furthermore, the levels of Leu 7 and 11a cells were significantly correlated (r=0.77, p<0.001), which was not seen in the control group. A strong inverse correlation was seen between changes in Leu 3a and 11a levels (r= 0.67, p < 0.01), and a positive correlation between 2a and 11a levels (r=0.68, p< 0.01). Leu7 levels were significantly increased in the Type2 diabetic patients, which is unexplained by differences in glucose control as HbA1 levels were similar in the three experimental groups.
Anti-lymphocyte antibodies
To determine whether anti-lymphocyte antibodies are present in the Type 1 diabetic patients of recent onset and define their possible relationship to peripheral blood lymphocyte abnormalities, we developed a method for detection of lymphocyte binding immunoglobulin using dual colour immunofluorescence. 
Discussion
We have found a reduction in the Leu 3a (helper) population of peripheral blood lymphocytes in new onset Type 1 diabetes and normal levels of Leu 2a + (cytotoxic/suppressor) cells. Type 1 diabetic patients of more than 4 months duration had intermediate 3a values, suggesting return of levels to normal with time. Our studies with anti-Leu 7 and 11a showed that the new onset patients may be divided into two groups :those with low Leu 3a and normal 7 and 11 levels, and those with low 7 and 11 a levels with normal Leu 3a. We found a significant increase in Leu 7 levels in Type 2 diabetes which cannot be explained on the basis of glucose control alone, but suggests either a previously unrecognised immune disturbance in this disease or change acquired with hyperglycaemia. Previous reports of peripheral blood lymphocytes in Type 1 diabetes are conflicting, describing both normal and low levels of helper and suppressor cells [3, 6, 7] . Pozzilli et al. used anti-Leu 3a to investigate peripheral blood lymphocytes in Type 1 diabetes and found decreased levels in diabetes of long standing [7] . It is possible that the differences we found in our study are due to using fresh, not frozen, cells, flow cytometry, and/or phycoerythrin conjugated antibodies which detect a higher proportion of cells.
The anti-natural killer antibodies Leu7 and 11a have not been previously studied in Type 1 diabetes. Wall et al. found an increase in HNK-l-positive cells in patients with sub-acute thyroiditis which shares many immunological features with Type 1 diabetes [17] . The discrepancies between our data and the raised killer cells found by Pozzilli et al. [4] may reflect differences in cells isolated by rosette formation. Recent work with multicolour immunofluorescence has shown overlap between the Leu 2a, 7 and 11a subsets [12] . Considering the changes we observed in Leu 7 and 11a, it is possible that previous observations of decreased suppressor cell numbers are actually due to a decrease in the lla+ and/or 7 +, 2a+ subpopulation. The significance of the reciprocol changes in 3a and 11a is unclear at this K. C. Herold et al.: Lymphocyte subpopulations in Type 1 diabetes time. Lanier et al. [12] showed that antibody-dependent cellular cytotoxicity and natural killer activity resides primarily within the 11a+ and to a lesser degree 7+ subsets. Although it is intriguing to postulate an abnormality in antibody-dependent cellular cytotoxicity due to disturbances in both effector and inducer cells, a more basic understanding of these cellular interactions is necessary.
We have shown that levels of antibody binding against Leu 3a + cells in patients with Type 1 diabetes of recent onset are significantly greater than those in control subjects. These differences are restricted to the 3a+ subpopulation. The absolute levels of binding against the 2a + cells in both diabetic and control subjects was higher than to 3a+ cells, which may be due to the brightness of the phycoerythrin anti-Leu 2a antibody. The levels of binding against the peripheral blood lymphocytes was low and we were unable to demonstrate a relationship of anti-lymphocyte antibodies to peripheral blood lymphocyte levels. Thus it is unlikely that anti-lymphocyte antibodies are able to account for the quantitative disturbances in peripheral blood lymphocytes that we have found. Rather, the relationship of anti-lymphocyte antibodies to thyroid antibodies suggests anti-lymphocyte antibodies are autoimmune markers. Functional studies in the presence or absence of the antibodies will be necessary to confirm this. Further study of lymphocyte surface antigens expressed during the onset of Type 1 diabetes are likely to add greatly to our understanding of these anti-lymphocyte antibodies.
A' variety of abnormalities of peripheral blood lymphocytes have been reported in Type 1 diabetes. Our data describe quantitative differences in T and natural killer cells which both corroborate [61 and are at variance [41 with earlier reports. The most likely explanation for these discrepancies is that Type 1 diabetic patients of recent onset are heterogenous in their immunological abnormalities. We have studied one possible mediator of immune disturbances and found that anti-lymphocyte antibodies are not a likely cause of peripheral blood lymphocyte disturbances, yet occur with other immune markers. However, such studies of peripheral phenomena can provide limited insight into the pathogenesis of the disease and further studies at the molecular and cellular level are needed. A more fundamental understanding of the immunological mediators is necessary before it will be possible to define the relationship between disturbances in peripheral blood lymphocytes and the pathogenesis of Type 1 diabetes.
